JP2022550851A5 - - Google Patents

Info

Publication number
JP2022550851A5
JP2022550851A5 JP2022520442A JP2022520442A JP2022550851A5 JP 2022550851 A5 JP2022550851 A5 JP 2022550851A5 JP 2022520442 A JP2022520442 A JP 2022520442A JP 2022520442 A JP2022520442 A JP 2022520442A JP 2022550851 A5 JP2022550851 A5 JP 2022550851A5
Authority
JP
Japan
Prior art keywords
alkylene
ala
pharmaceutically acceptable
acceptable salt
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054137 external-priority patent/WO2021067861A1/en
Publication of JP2022550851A publication Critical patent/JP2022550851A/ja
Publication of JP2022550851A5 publication Critical patent/JP2022550851A5/ja
Pending legal-status Critical Current

Links

JP2022520442A 2019-10-04 2020-10-02 カンプトテシンペプチドコンジュゲート Pending JP2022550851A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962911060P 2019-10-04 2019-10-04
US62/911,060 2019-10-04
PCT/US2020/054137 WO2021067861A1 (en) 2019-10-04 2020-10-02 Camptothecin peptide conjugates

Publications (2)

Publication Number Publication Date
JP2022550851A JP2022550851A (ja) 2022-12-05
JP2022550851A5 true JP2022550851A5 (cg-RX-API-DMAC7.html) 2023-10-04

Family

ID=73013821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520442A Pending JP2022550851A (ja) 2019-10-04 2020-10-02 カンプトテシンペプチドコンジュゲート

Country Status (10)

Country Link
US (1) US20240277860A1 (cg-RX-API-DMAC7.html)
EP (1) EP4037717A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022550851A (cg-RX-API-DMAC7.html)
KR (1) KR20220079606A (cg-RX-API-DMAC7.html)
CN (1) CN114929284A (cg-RX-API-DMAC7.html)
AU (1) AU2020356955A1 (cg-RX-API-DMAC7.html)
CA (1) CA3152316A1 (cg-RX-API-DMAC7.html)
IL (1) IL291686A (cg-RX-API-DMAC7.html)
MX (1) MX2022003930A (cg-RX-API-DMAC7.html)
WO (1) WO2021067861A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936169A (zh) * 2018-04-06 2020-11-13 西雅图遗传学公司 喜树碱肽缀合物
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
KR20230023650A (ko) * 2020-05-13 2023-02-17 씨젠 인크. 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법
IL305886A (en) * 2021-03-18 2023-11-01 Seagen Inc Selective release of drugs from internalized conjugates of biologically active compounds
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
KR20250004952A (ko) * 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
WO2023217227A1 (zh) * 2022-05-12 2023-11-16 先声再明医药有限公司 喜树碱类衍生物及配体-药物偶联物
AU2023278370A1 (en) * 2022-05-30 2025-01-09 Medilink Therapeutics (Suzhou) Co., Ltd. Preparation method for drug linker conjugate and intermediate thereof
WO2024020734A1 (en) * 2022-07-25 2024-02-01 Immunogen, Inc. Novel processes for preparing camptothecin derivatives
JP2025529237A (ja) * 2022-08-30 2025-09-04 ピノットバイオ インコーポレイテッド カンプトセシン系薬物が抗原結合親和性の低い抗体にリンカーを介して連結された抗体薬物複合体
KR20240035370A (ko) * 2022-09-08 2024-03-15 주식회사 피노바이오 신규 캄토테신 유도체 및 이를 포함하는 운반체-약물 접합체
KR20250079213A (ko) 2022-10-09 2025-06-04 라노바 메디신즈 리미티드 화합물, 조성물 및 방법
WO2024114318A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024230301A1 (zh) * 2023-05-09 2024-11-14 诺灵生物医药科技(北京)有限公司 一种抗体偶联药物及其用途
CN119300868B (zh) * 2023-05-11 2026-03-13 映恩生物科技(上海)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
CN122374343A (zh) 2023-11-30 2026-07-10 江苏康宁杰瑞生物制药有限公司 包含pd-l1结合分子与双特异性抗体-药物偶联物的组合物及其用途
AU2024415931A1 (en) 2023-12-27 2026-07-16 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Multi-specific antibody targeting her3 and trop2 and conjugate thereof
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1731174A3 (en) 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
US6629995B1 (en) * 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
US6825206B1 (en) * 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US8067546B2 (en) 2005-04-19 2011-11-29 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US20070116643A1 (en) 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
CN101273024A (zh) 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
KR101641345B1 (ko) * 2007-10-12 2016-07-20 시애틀 지네틱스, 인크. 항체-약물 접합체를 이용한 병용 요법
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
CN104822656B (zh) 2012-05-15 2018-05-01 西雅图基因公司 自稳定接头偶联物
US20160106861A1 (en) * 2013-04-26 2016-04-21 Spirogen Sarl Axl antibody-drug conjugate and its use for the treatment of cancer
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
CN105813653B (zh) * 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
KR20170128256A (ko) 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. Cd48 항체 및 이의 접합체
KR20180021705A (ko) 2015-06-30 2018-03-05 시애틀 지네틱스, 인크. 항-ntb-a 항체 및 관련 조성물 및 방법
JP2021095424A (ja) * 2018-03-28 2021-06-24 持田製薬株式会社 抗癌剤結合アルギン酸誘導体
CN111936169A (zh) * 2018-04-06 2020-11-13 西雅图遗传学公司 喜树碱肽缀合物
TWI920652B (zh) * 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
CN109675050A (zh) * 2018-12-27 2019-04-26 浙江工业大学 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用

Similar Documents

Publication Publication Date Title
JP2021521111A5 (cg-RX-API-DMAC7.html)
JP7407973B2 (ja) 抗体薬物複合体、その調製方法、およびその使用
RU2563830C2 (ru) Лечение остеоартрита и боли
ES2614636T3 (es) Moléculas de anticuerpos que se unen a IL-17 humana
JP2024544520A5 (cg-RX-API-DMAC7.html)
JP2023530128A (ja) 細胞結合分子とカンプトテシン類縁体との共役体
JP2023535598A5 (cg-RX-API-DMAC7.html)
ES2733735T3 (es) Anticuerpos contra CSF-1R
JP2020509027A5 (cg-RX-API-DMAC7.html)
ES2993153T3 (en) Pan elr+ cxc chemokine antibodies
TW202108181A (zh) 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
JP2020504112A5 (cg-RX-API-DMAC7.html)
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
WO2018038684A1 (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
WO2019050780A1 (en) COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS
EP4155319A1 (en) 4-1bb binding protein and application thereof
CN110022903A (zh) Met抗体药物缀合物
JP2023515675A5 (cg-RX-API-DMAC7.html)
IL258337B2 (en) Antibodies that bind human cannabinoid receptor 1
CN115501347A (zh) 抗her2抗体药物偶联物和parp抑制剂联合在制备治疗肿瘤的药物中的用途
CN111973753B (zh) 抗肿瘤的联合用药物及其应用
JP2026001086A (ja) 抗cd30抗体薬物複合体療法の副作用を軽減する方法
KR102239752B1 (ko) 종양 특이적 약물복합체와 항pd-l1 항체를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물
KR20230023650A (ko) 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법